Milestone Secures Patent For CARDAMYST’s Repeat Dose Regimen

Milestone Pharmaceuticals recently announced it received a Notice of Allowance from the USPTO enabling patent protection of how etripamil nasal spray (CARDAMYST™) can be used to treat patients with paroxysmal supraventricular tachycardia (PSVT) by administering two repeat doses. Once U.S. Patent Application No. 17/865,697 receives the granting of the patent, it will maintain CARDAMYST’s intellectual property coverage in the U.S. until July 2042 and extend its exclusive rights by six years. 

“This added protection will position us to optimize the commercial value of CARDAMYST. The new patent underscores Milestone’s continued development of our patent portfolio and our commitment to innovation in cardiology,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals.

Patients can receive an additional 70 mg dose of etripamil nasal spray following a ten-minute observation period if their PSVT symptoms endure according to the regimen evaluated during the RAPID Phase 3 trial. The new drug application submitted by Milestone for CARDAMYST undergoes present FDA evaluation and has its PDUFA target set for March 27, 2025. CARDAMYST will enter the market in mid-2025 if the FDA approves the treatment, which will carry the FDA-conditionally approved brand name CARDAMYST.